TY - JOUR
T1 - Arsenic mobilizes Langerhans cell migration and induces Th1 response in epicutaneous protein sensitization via CCL21
T2 - A plausible cause of decreased Langerhans cells in arsenic-induced intraepithelial carcinoma
AU - Lee, Chih Hung
AU - Hong, Chien Hui
AU - Yu, Chia Li
AU - Wang, Li Fang
AU - Clausen, Björn E.
AU - Liao, Wei Ting
AU - Huang, Shau Ku
AU - Chen, Gwo Shing
AU - Yu, Hsin Su
N1 - Funding Information:
We thank our patients with arsenic-induced Bowen's disease for their kind participation in this study and Dr. Keisuke Nagao in Keio University, Japan, for his valuable comments on this study. We would also like to thank the common laboratory facility and animal facility of Kaohsiung Medical University. This work is supported by grants from National Science Council ( NSC95-2314-B-037-024, NSC96-2314-B-037-043, 100-2314-B-037-039-MY3 ) (Dr. Lee), National Health Research Institute ( NHRI-EO-096-PP-11; NHRI CN-PD-9611P; NHRI-EX101-9703BI ) (Dr. Yu), Kaohsiung Medical University ( KMU-QA096005 ) (Dr. Lee), and KMU Center of Excellence for Environmental Medicine ( 98.2b ) (Dr. Yu). BEC is a VIDI fellow of The Netherlands Organization for Scientific Research. The research of SKH was supported, in part, by NIH ( AI-052468 and AI073610 ).
PY - 2012/5/1
Y1 - 2012/5/1
N2 - Arsenic, still a significant environmental threat in several regions in the world, induces various cancers, including lungs, skin, and bladder. Arsenic-induced Bowen's disease (As-BD) is generally an indolent cutaneous intraepithelial carcinoma in susceptible people. Patients with As-BD have been found to have attenuated contact hypersensitivity. Skin samples collected from these patients have reduced numbers of Langerhans cells (LCs), the major epidermal antigen presenting cells expressing Langerins. This study uses an epicutaneous protein sensitization model to investigate the mechanism through which LCs are decreased in As-BD. It further investigates the possibility that arsenic alters LC migration and polarizes Th responses. To do this, we patch-sensitized Balb/c mice or DT-treated Langerin-DTR mice (conditional depletion of Langerin+ cells) with OVA or PBS, and fed them water containing 300 ppb arsenic or regular water for 200 μl for five days. Ninety-six hours after OVA sensitization, Langerin+EpCAM+ cells in arsenic-treated WT mice were significantly increased in draining lymph nodes and decreased in epidermis without changes in the dermis. Lymph node cells from arsenic-treated WT mice were found to proliferate more than lymph node cells from control PBS-treated mice after OVA challenge in vitro. They also secreted more IFN-γ and IL-12, but not IL-4, IL-13, or IL-17. However, cell proliferation and the induction of IFN-γ by arsenic were found to be abolished in DT-treated Langerin-DTR mice. The expressions of CCL21 and CXCL12 were also increased in lymph nodes from arsenic-treated WT mice. The administration of a neutralizing antibody against CCL21, but not CXCL12, abolished the increase of LCs in lymph nodes in vivo. The results of this study, the first to study oral arsenic polarization of Th1 responses in epicutaneous protein sensitization through CCL21-mediated LC migration, suggest the chronicity of As-BD without invasion might result from enhanced Th1 responses and altered LC migrations by arsenic.
AB - Arsenic, still a significant environmental threat in several regions in the world, induces various cancers, including lungs, skin, and bladder. Arsenic-induced Bowen's disease (As-BD) is generally an indolent cutaneous intraepithelial carcinoma in susceptible people. Patients with As-BD have been found to have attenuated contact hypersensitivity. Skin samples collected from these patients have reduced numbers of Langerhans cells (LCs), the major epidermal antigen presenting cells expressing Langerins. This study uses an epicutaneous protein sensitization model to investigate the mechanism through which LCs are decreased in As-BD. It further investigates the possibility that arsenic alters LC migration and polarizes Th responses. To do this, we patch-sensitized Balb/c mice or DT-treated Langerin-DTR mice (conditional depletion of Langerin+ cells) with OVA or PBS, and fed them water containing 300 ppb arsenic or regular water for 200 μl for five days. Ninety-six hours after OVA sensitization, Langerin+EpCAM+ cells in arsenic-treated WT mice were significantly increased in draining lymph nodes and decreased in epidermis without changes in the dermis. Lymph node cells from arsenic-treated WT mice were found to proliferate more than lymph node cells from control PBS-treated mice after OVA challenge in vitro. They also secreted more IFN-γ and IL-12, but not IL-4, IL-13, or IL-17. However, cell proliferation and the induction of IFN-γ by arsenic were found to be abolished in DT-treated Langerin-DTR mice. The expressions of CCL21 and CXCL12 were also increased in lymph nodes from arsenic-treated WT mice. The administration of a neutralizing antibody against CCL21, but not CXCL12, abolished the increase of LCs in lymph nodes in vivo. The results of this study, the first to study oral arsenic polarization of Th1 responses in epicutaneous protein sensitization through CCL21-mediated LC migration, suggest the chronicity of As-BD without invasion might result from enhanced Th1 responses and altered LC migrations by arsenic.
KW - Arsenic
KW - Bowen's disease
KW - CCL21
KW - IFN-gamma
KW - Langerhans cells
UR - http://www.scopus.com/inward/record.url?scp=84862778090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862778090&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2012.01.028
DO - 10.1016/j.bcp.2012.01.028
M3 - Article
C2 - 22321510
AN - SCOPUS:84862778090
SN - 0006-2952
VL - 83
SP - 1290
EP - 1299
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 9
ER -